Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

Breast cancer outcomes are significantly impacted by race and immune responses, particularly among Black patients with triple-negative subtypes, emphasizing the need to understand these disparities and develop more effective treatment strategies.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.